Search results
Treatment options include surgery, cancer medicines and/or radiotherapy, administered alone or in combination. A multidisciplinary team of cancer professionals recommends the best possible treatment plan based on tumour type, cancer stage, clinical and other factors.
- WHO Guidelines for the pharmacological and radiotherapeutic management ...
The World Health Organization (WHO) has developed Guidelines...
- WHO Guidelines for the pharmacological and radiotherapeutic management ...
1 sty 2019 · The World Health Organization (WHO) has developed Guidelines for the pharmacologic and radiotherapeutic management of cancer pain in adults and adolescents to provide evidence-based guidance to initiating and managing cancer pain.
Despite published guidelines and educational programs on the assessment and treatment of cancer-related pain, in any stage of oncological disease, unrelieved pain continues to be a substantial worldwide public health concern in patients with either solid or hematological malignancies.
assessment of patients with pain. According to the literature, most patients with advanced cancer have at least two types of cancer-related pain which derive from a variety of etiologies [9, 10]. Sixty-nine per cent of patients rate their worst pain at a level that impaired their ability to function [11].
Cancer pain can be a complication of cancer or its treatment and can negatively affect the functional status and quality of life of patients. Get comprehensive, practical information on the screening, assessment, and management of cancer-related pain in this summary for clinicians.
The following agents are not recommended for patients with cancer: (1) mixed agonist-antagonists (eg, butorphanol, pentazocine); (2) meperidine; and (3) placebos. Mixed agonist-antagonists should not be used in combination with opioid agonist drugs for cancer pain management.
3 lut 2022 · Improved access to oral morphine is strongly recommended for the treatment of moderate to severe cancer pain, suffered by over 80% of people with cancer in the terminal phase. WHO response
